The lung as a route for systemic delivery of therapeutic proteins and peptides

Respiratory Research

Volumn 2, Issue 4, 2001, Pages 198-209

  Agu, Remigius Uchenna ^a   Ugwoke, Michael Ikechukwu ^b   Armand, Michoel ^a   Kinget, Renaat ^a   Verbeke, Norbert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b OctoPlus NV   (Netherlands)

Author keywords

Lung; Peptides; Proteins; Pulmonary absorption; Systemic delivery

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; AUTOANTIGEN; BETA CYCLODEXTRIN; CALCITONIN; CETRORELIX; CHLOROFLUOROCARBON; CYCLOSPORIN A; DESMOPRESSIN; DETIRELIX; ENZYME INHIBITOR; FLUORINATED HYDROCARBON; FOLLITROPIN; GAMMA CYCLODEXTRIN; GLYCOLIC ACID; GONADORELIN; GROWTH HORMONE; IMMUNOGLOBULIN; INSULIN; LEUPRORELIN; LIPOSOME; OLEIC ACID; PEPTIDE; POLYLACTIC ACID; PROPELLANT; PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYROTROPIN; UNINDEXED DRUG; VASOPRESSIN DERIVATIVE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SAFETY; DRY POWDER; HUMAN; INHALER; LUNG ALVEOLUS EPITHELIUM; LUNG BLOOD VESSEL; METERED DOSE INHALER; MOUSE; NEBULIZER; NONHUMAN; RAT; REVIEW;

ABSORPTION; ANIMALS; CALCITONIN; DEAMINO ARGININE VASOPRESSIN; DRUG DELIVERY SYSTEMS; GONADOTROPIN-RELEASING HORMONE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; INSULIN; LUNG; PEPTIDES; PROTEINS; THYROTROPIN;

EID: 0035719828     PISSN: 14659921     EISSN: None     Source Type: Journal    
DOI: 10.1186/rr58     Document Type: Review

References (73)

1. Recent progress in protein and peptide delivery by non-invasive routes
2. Is total particle dose more important than particle distribution
3. Pulmonary delivery of human protein C and factor IX
4. Clinical comparison of inhaled busesonide delivered either via pressurized metered dose inhaler or Turbuhaler®
5. Flow-dependent effect of formoterol dry powder inhaled from the Aerolizer®
6. Delivery of biotherapeutics by inhalation aerosol
7. Systemic delivery of peptides and proteins across absorptive mucosae
8. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs
9. Pulmonary biotransformation of insulin in rat and rabbit
10. Proteolytic enzymes as a limitation for pulmonary absorption of insulin: In vitro and in vivo investigations
11. Susceptibility of insulin to proteolysis in rat lung homogenates and its protection from proteolysis by various protease inhibitors
12. Insulin across respiratory mucosa by aerosol delivery
13. The pharmacokinetics of pulmonary-delivered insulin: A comparison of intratracheal and aerosol administration to the rabbit
14. Intratracheal delivery of insulin absorption from solution and aerosol by rat lung
15. A new approach for insulin delivery via the pulmonary route: Design and pharmacokinetics in non-diabetics rabbits
16. An exploration of intrapulmonary insulin administration in anaesthetized and mechanically ventilated pigs
17. About inhalation of insulin
18. Intrapulmonary administration of insulin to healthy volunteers
19. Preliminary study of the efficiency of insulin aerosol delivered by oral inhalation in diabetic patients
20. The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes
21. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus
22. Inhaled technosphere: Insulin shows a low variability in metabolic action in type 2 diabetic patients
23. Results of a dose-response study with a new insulin inhaler formulation
24. Parenteral absorption of insulin from the lung in diabetic children
25. Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus (NIDDM)
26. Treatment of type 1 diabetes mellitus with inhaled human insulin: A 3-month, multicenter trial
27. Treatment of type 2 diabetes mellitus with inhaled human insulin: A 3-month, multicenter trial
28. Improved patient satisfaction with inhaled insulin in subjects with type 2 diabetes mellitus: Results from a multicenter randomized controlled trial
29. Improved patient satisfaction with inhaled insulin in subjects with type 1 diabetes mellitus after one year: Results from a multicenter extension trial
30. Sustained efficacy and pulmonary safety of inhaled insulin during two years of outpatient therapy
31. A comparison of the pharmacokinetics and pharmacodynamics of inhaled insulin administered as different strength solutions to healthy volunteers
32. The mode of inhalation influences the pharmacokinetics and pharmacodynamics of pulmonary delivered insulin in healthy fasted volunteers
33. A comparison of the pharmacodynamic effects of inhaled insulin versus subcutaneous insulin in type 1 diabetic patients
34. Pharmacokinetics and pharmcodynamics of inhaled versus subcutaneous insulin in subjects with type 1 diabetes: A glucose clamp study [abstract]
35. Adjunctive therapy with inhaled human insulin in type 2 diabetic patients failing oral agents: A multicenter phase II trial
36. Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormone
37. Intratracheal delivery of peptide and protein agents: Absorption from solution and dry powder by rat lung
38. Lung to blood passage of human growth hormone after intratracheal instillation: Stimulation of growth in hypophysectomized rats
39. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits
40. Cyclodextrins as mucosal absorption promoters of insulin III: Pulmonary route of delivery
41. Lanthanides enhance pulmonary absorption of insulin
42. Intra-individual variability of metabolic effect of inhaled insulin together with an absorption enhancer
43. Study of pulmonary delivery of salmon calcitonin in rats: Effects of protease inhibitors and absorption enhancers
44. 1,7)-Eel calcitonin by various protease inhibitors in rats
45. 1,7)-Eel calcitonin by various absorption enhancers and their pulmonary toxicity in rats
46. Large porous particles for pulmonary drug delivery
47. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanosphere to prolong hypoglycemic effect
48. Pulmonary delivery of free and liposomal insulin
49. Effect of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption
50. SK&F 110679: Comparison of absorption following oral or respiratory administration
51. Pulmonary delivery of peptide drugs: Effect of particle size on bioavailability of leuprolide acetate in healthy volunteers
52. Formulations of a nonapeptide: In vitro and in vivo studies
53. Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: Some pharmacokinetic and clinical issues
54. Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in briefly anesthetized dog
55. Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthethized awake sheep
56. Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rat
57. Permeability of the respiratory tract to different sized macromolecules after intratracheal instillation in young and adult rats
58. Lung to blood passage of albumin and a nonapeptide after intratracheal instillation in the young developing pig
59. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract
60. γδ T cells as mediators of mucosal tolerance: The autoimmune diabetes model
61. Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes
62. 1, assessed in hamsters
63. Systemic absorption and activity of recombinant consensus interferons after intratracheal intillation and aerosol administration
64. Pulmonary absorption of recombinant methionyl human granulocyte colony stimulating factor (r-huG-CSF) after intratracheal instillation to the hamster
65. Pulmonary delivery of powders and solutions containing granulocyte colony-stimulating factor (r-huG-CSF) to the rabbit
66. Pulmonary delivery of intratracheally instilled and aerosolized cyclosporin A to young and adult rats
67. Pulmonary absorption of polyethylene glycolated recombinant human granulocyte colony stimulating factor (PEGr-huG-CSF)
68. Safety of inhaled proteins for therapeutic use
69. Pulmonary effect of chronic exposure to liposome aerosols in mice
70. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes